Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug duo aims to attack tough stomach cancers

NCT ID NCT05041153

Summary

This is an early, small study to see if a combination of two drugs can help control advanced stomach or gastroesophageal cancer that has spread or cannot be removed by surgery. The trial is for adults whose cancer has continued to grow despite trying standard treatments. One drug helps the immune system fight the cancer, while the other aims to cut off the tumor's blood supply and block its growth signals.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

ADVANCED GASTRIC ADENOCARCINOMA ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA CLINICAL STAGE III GASTRIC CANCER AJCC V8 CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 CLINICAL STAGE IV GASTRIC CANCER AJCC V8 CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 CLINICAL STAGE IVA GASTRIC CANCER AJCC V8 CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 CLINICAL STAGE IVB GASTRIC CANCER AJCC V8 CLINICAL STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 METASTATIC GASTRIC ADENOCARCINOMA METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PATHOLOGIC STAGE III GASTRIC CANCER AJCC V8 PATHOLOGIC STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 PATHOLOGIC STAGE IIIA GASTRIC CANCER AJCC V8 PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 PATHOLOGIC STAGE IIIB GASTRIC CANCER AJCC V8 PATHOLOGIC STAGE IIIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 PATHOLOGIC STAGE IIIC GASTRIC CANCER AJCC V8 PATHOLOGIC STAGE IV GASTRIC CANCER AJCC V8 PATHOLOGIC STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 PATHOLOGIC STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE III GASTRIC CANCER AJCC V8 POSTNEOADJUVANT THERAPY STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IIIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IV GASTRIC CANCER AJCC V8 POSTNEOADJUVANT THERAPY STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 UNRESECTABLE GASTRIC ADENOCARCINOMA UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA